66 related articles for article (PubMed ID: 32307332)
1. Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis.
Yuan H; Mao J; Liu C; Fu H; Guo W; Ding G
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):845-854. PubMed ID: 32307332
[TBL] [Abstract][Full Text] [Related]
2. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
3. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review.
Zhang R; Wang F; You Z; Deng D; He J; Yan W; Quan J; Wang J; Yan S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):82. PubMed ID: 38319412
[TBL] [Abstract][Full Text] [Related]
4. Impact of Center Volume on Cardiopulmonary and Mortality Outcomes after Immune-Checkpoint Inhibitors for Cancer: A Systematic Review and Meta-Analysis.
Rahouma M; Mynard N; Baudo M; Khairallah S; Al-Thani S; Dabsha A; Shmushkevich S; Shoeib O; Hossny M; Eldeeb E; Aziz H; Abdelkarim N; Gaudino M; Mohamed A; Girardi L; Zhang J; Mutti L
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539471
[TBL] [Abstract][Full Text] [Related]
5. Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.
Matsumoto H; Somekawa K; Horita N; Ueda S; Kaneko M; Kaneko A; Fukuda N; Izawa A; Kamimaki C; Tanaka K; Murohashi K; Fuji H; Tagami Y; Aoki A; Watanabe K; Hara Y; Kobayashi N; Kaneko T
Ther Adv Med Oncol; 2023; 15():17588359231198453. PubMed ID: 37720498
[TBL] [Abstract][Full Text] [Related]
6. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research.
Yip R; Arnolda G; Lamprell K; Nic Giolla Easpaig B; Chittajallu R; Delaney G; Olver I; Liauw W; Braithwaite J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212121
[TBL] [Abstract][Full Text] [Related]
7. In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse events.
Bertolaccini L
Ann Intern Med; 2024 Apr; 177(4):JC42. PubMed ID: 38560904
[TBL] [Abstract][Full Text] [Related]
8. Causes and Clinical Presentation of Drug-Induced Dermatomyositis: A Systematic Review.
Caravan S; Lopez CM; Yeh JE
JAMA Dermatol; 2024 Feb; 160(2):210-217. PubMed ID: 38198130
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for stereotactic body radiation before immune checkpoint inhibitor therapy for advanced hepatocellular carcinoma?
Mukherjee S
Transl Cancer Res; 2023 Aug; 12(8):2229-2231. PubMed ID: 37701123
[No Abstract] [Full Text] [Related]
10. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.
Ryoo BY; Merle P; Kulkarni AS; Cheng AL; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Daniele B; Norquist JM; Chen E; Siegel AB; Zhu AX; Finn RS; Kudo M
Cancer; 2021 Mar; 127(6):865-874. PubMed ID: 33231873
[TBL] [Abstract][Full Text] [Related]
12. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
13. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Chen S; Huang Z; Jia W; Tao H; Zhang S; Ma J; Liu Z; Wang J; Wang L; Cui P; Zhang Z; Huang D; Wu Z; Zheng X; Hu Y
J Hepatocell Carcinoma; 2020; 7():289-299. PubMed ID: 33173757
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
15. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
Park R; Eshrat F; Al-Jumayli M; Saeed A; Saeed A
Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784389
[TBL] [Abstract][Full Text] [Related]
16. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.
Kudo M
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32349374
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.
Wang Y; Kong D; Wang C; Chen J; Li J; Liu Z; Li X; Wang Z; Yao G; Wang X
Technol Cancer Res Treat; 2020; 19():1533033820967454. PubMed ID: 33084525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
